BELLICUM PHARMACEUTICALS, INC 4
4 · BELLICUM PHARMACEUTICALS, INC · Filed Dec 5, 2016
Insider Transaction Report
Form 4
Spencer David M.
Chief Scientific Officer
Transactions
- Sale
Common Stock
2016-12-01$17.17/sh−2,967$50,942→ 153,115 total - Sale
Common Stock
2016-12-01$18.04/sh−2,033$36,682→ 151,082 total
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 21, 2016 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.74 to $17.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.78 to $18.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.Select